FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171679244> ?p ?o ?g. }

• W3171679244 endingPage "4993" @default.
• W3171679244 startingPage "4983" @default.
• W3171679244 abstract "Abstract Purpose: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer enrolled in the BROCADE3 trial who received crossover veliparib monotherapy after disease progression on placebo plus carboplatin/paclitaxel. Patients and Methods: Eligible patients (N = 513) were randomized 2:1 to veliparib plus carboplatin/paclitaxel or placebo plus carboplatin/paclitaxel; patients had variable platinum-free intervals (PFI) at progression. In the placebo arm, patients were eligible to receive crossover veliparib monotherapy (300–400 mg twice daily continuous). Antitumor activity and adverse events were assessed during crossover veliparib treatment. BRCA reversion mutations at crossover were analyzed retrospectively using next-generation sequencing on plasma circulating tumor DNA (ctDNA). Results: Seventy-five patients in the placebo plus carboplatin/paclitaxel arm received ≥1 dose of crossover veliparib postprogression (mean treatment duration: 154 days). Eight of 50 (16%) patients with measurable disease had a RECIST v1.1 response. Activity was greater in patients with PFI ≥180 days compared with &lt;180 days [responses in 23.1% (3/13) vs. 13.5% (5/37) of patients]. BRCA reversion mutations that restored protein function were detected in ctDNA from 4 of 28 patients tested, and the mean duration of crossover veliparib monotherapy was &lt;1 month in these 4 patients versus 7.49 months in patients lacking reversion mutations. The most frequent adverse events were nausea (61%), vomiting (29%), and fatigue (24%). Conclusions: Crossover veliparib monotherapy demonstrated limited antitumor activity in patients who experienced disease progression on placebo plus carboplatin/paclitaxel. PFI appeared to affect veliparib activity. BRCA reversion mutations may promote cross-resistance and limit veliparib activity following progression on platinum." @default.
• W3171679244 created "2021-06-22" @default.
• W3171679244 creator A5011540763 @default.
• W3171679244 creator A5013548755 @default.
• W3171679244 creator A5015127974 @default.
• W3171679244 creator A5021894535 @default.
• W3171679244 creator A5024527435 @default.
• W3171679244 creator A5029076260 @default.
• W3171679244 creator A5036245359 @default.
• W3171679244 creator A5038401734 @default.
• W3171679244 creator A5038783087 @default.
• W3171679244 creator A5042898910 @default.
• W3171679244 creator A5043634794 @default.
• W3171679244 creator A5050390557 @default.
• W3171679244 creator A5052697647 @default.
• W3171679244 creator A5056530735 @default.
• W3171679244 creator A5056565799 @default.
• W3171679244 creator A5059093147 @default.
• W3171679244 creator A5059240684 @default.
• W3171679244 creator A5079216912 @default.
• W3171679244 date "2021-06-15" @default.
• W3171679244 modified "2023-10-02" @default.
• W3171679244 title "Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover)" @default.
• W3171679244 cites W1973268287 @default.
• W3171679244 cites W2009007206 @default.
• W3171679244 cites W2097026108 @default.
• W3171679244 cites W2105496345 @default.
• W3171679244 cites W2131670056 @default.
• W3171679244 cites W2298876126 @default.
• W3171679244 cites W2302561381 @default.
• W3171679244 cites W2375577403 @default.
• W3171679244 cites W2526716574 @default.
• W3171679244 cites W2528228811 @default.
• W3171679244 cites W2589334089 @default.
• W3171679244 cites W2597062310 @default.
• W3171679244 cites W2599047065 @default.
• W3171679244 cites W2608211931 @default.
• W3171679244 cites W2621271973 @default.
• W3171679244 cites W2627871710 @default.
• W3171679244 cites W2737389832 @default.
• W3171679244 cites W2741214285 @default.
• W3171679244 cites W2746672093 @default.
• W3171679244 cites W2754242788 @default.
• W3171679244 cites W2754327139 @default.
• W3171679244 cites W2763602017 @default.
• W3171679244 cites W2786732135 @default.
• W3171679244 cites W2801956643 @default.
• W3171679244 cites W2808408940 @default.
• W3171679244 cites W2886477543 @default.
• W3171679244 cites W2901506506 @default.
• W3171679244 cites W2990895669 @default.
• W3171679244 cites W3005153366 @default.
• W3171679244 cites W3006950991 @default.
• W3171679244 cites W3081315565 @default.
• W3171679244 cites W3093351227 @default.
• W3171679244 doi "https://doi.org/10.1158/1078-0432.ccr-21-0748" @default.
• W3171679244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34131001" @default.
• W3171679244 hasPublicationYear "2021" @default.
• W3171679244 type Work @default.
• W3171679244 sameAs 3171679244 @default.
• W3171679244 citedByCount "8" @default.
• W3171679244 countsByYear W31716792442021 @default.
• W3171679244 countsByYear W31716792442022 @default.
• W3171679244 countsByYear W31716792442023 @default.
• W3171679244 crossrefType "journal-article" @default.
• W3171679244 hasAuthorship W3171679244A5011540763 @default.
• W3171679244 hasAuthorship W3171679244A5013548755 @default.
• W3171679244 hasAuthorship W3171679244A5015127974 @default.
• W3171679244 hasAuthorship W3171679244A5021894535 @default.
• W3171679244 hasAuthorship W3171679244A5024527435 @default.
• W3171679244 hasAuthorship W3171679244A5029076260 @default.
• W3171679244 hasAuthorship W3171679244A5036245359 @default.
• W3171679244 hasAuthorship W3171679244A5038401734 @default.
• W3171679244 hasAuthorship W3171679244A5038783087 @default.
• W3171679244 hasAuthorship W3171679244A5042898910 @default.
• W3171679244 hasAuthorship W3171679244A5043634794 @default.
• W3171679244 hasAuthorship W3171679244A5050390557 @default.
• W3171679244 hasAuthorship W3171679244A5052697647 @default.
• W3171679244 hasAuthorship W3171679244A5056530735 @default.
• W3171679244 hasAuthorship W3171679244A5056565799 @default.
• W3171679244 hasAuthorship W3171679244A5059093147 @default.
• W3171679244 hasAuthorship W3171679244A5059240684 @default.
• W3171679244 hasAuthorship W3171679244A5079216912 @default.
• W3171679244 hasBestOaLocation W31716792441 @default.
• W3171679244 hasConcept C104317684 @default.
• W3171679244 hasConcept C121608353 @default.
• W3171679244 hasConcept C126322002 @default.
• W3171679244 hasConcept C142724271 @default.
• W3171679244 hasConcept C143998085 @default.
• W3171679244 hasConcept C182979987 @default.
• W3171679244 hasConcept C197934379 @default.
• W3171679244 hasConcept C204787440 @default.
• W3171679244 hasConcept C27081682 @default.
• W3171679244 hasConcept C2776694085 @default.
• W3171679244 hasConcept C2778239845 @default.
• W3171679244 hasConcept C2779138821 @default.
• W3171679244 hasConcept C2780194787 @default.
• W3171679244 hasConcept C2781312401 @default.

• next